OTPERS	Į.		
Form PTO-1595(Plev. 07/05) OMB No. 065250027 (exp. 6/30/2008)	- 17 - 2005 3. DEPARTMENT OF COMMERCE description of the state of the		
REC	3101315		
To the Director of the U.S. Patent and Trademark Office: Plea	se record the attached documents or the new address(es) below.		
1. Name of conveying party(ies) Yukio Sugimura, Executive VP & Representative Sankyo Co. Ltd.	2. Name and address of receiving party(ies) Name: X-ceptor Inc. Internal Address:		
Additional name(s) of conveying party(ies) attached? Yes ✓ No. 3. Nature of conveyance/Execution Date(s): Execution Date(s) 9/26/2005	Street Address: 4757 Nexus Center Dr. Suite 200		
✓ Assignment Merger □ Security Agreement Change of Name	City: San Diego State: California Country: USA Zip: 92121		
Joint Research Agreement Government Interest Assignment Executive Order 9424, Confirmatory License			
Other	Additional name(s) & address(es) attached? Yes		
A. Patent Application No.(s) 10/738,964 US03/40275 Taiwan 92136405 EP3814127.1 AU33012AA Additional numbers a			
5. Name and address to whom correspondence concerning document should be mailed:	6. Total number of applications and patents involved: 5		
Name: Carmen Pili Ekstrom Internal Address:	7. Total fee (37 CFR 1.21(h) & 3.41) \$ 200.00 Authorized to be charged by credit card Authorized to be charged to deposit account		
Street Address: Exelixis, Inc., 170 Harbor Way	Enclosed None required (government interest not affecting title		
City: South San Francisco	8. Payment Information		
State: <u>CA</u> Zip: <u>94083-0511</u>	a. Credit Card Last 4 Numbers Expiration Date		
Phone Number: 650 837-7014			
Fax Number: 650 837-7179	b. Deposit Account Number <u>501108</u> Authorized User Name <u>Carmen Ekstrom</u>		
Email Address: cekstrom@exelixis.com			
9. Signature: Signature	47loS Date		
DBYRNE 00000308 501108 19738364 Pili Ekstrom Name of Person Signing	Total number of pages including cover sheet, attachments, and documents:		
Documents to be recorded (including cover sheet	et) should be faxed to (571) 273-0140, or mailed to: of the USPTO, P.O.Box 1450, Alexandria, V.A. 22313-1450		

PATENT REEL: 017075 FRAME: 0250

PATENT ASSIGNMENT

This PATENT ASSIGNMENT (this "Assignment") is entered into by **Sankyo Co., Ltd.**, a joint stock company formed under the laws of Japan with offices at 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, Japan ("Assignor"), as assignor, in favor of **X-Ceptor**, **Inc.**, a Delaware corporation with offices at 4757 Nexus Center Drive, Suite 200, San Diego, California 92121 (the "Assignee") that is a wholly-owned-subsidiary of Exelixis Inc., as assignee, with reference to the following facts and circumstances:

Assignor and Assignee previously entered into a Collaboration Agreement on March 19, 2001, as amended by letter on June 6, 2001 and October 21, 2001, and subsequently amended by agreement on May 8, 2002, September 20, 2003 and December 12, 2003, to file, prosecute and maintain all jointly owned patent applications during a mutual collaboration relating to Isoquinolinone derivatives and their use as therapeutic agents.

Assignor and Assignee jointly own all the right, title and interest in and to Isoquinolinone derivatives and their use as therapeutic agents described and claimed in patent applications provided in Schedule 1 (the "Patent Applications"). Assignee desires to acquire, and Assignor desires to assign, all of Assignor's right, title and interest in and to the Patent Applications, and all future patents which may be granted therefor throughout the world, and all divisions, reissues, reexaminations, substitutions, continuations, continuations-in-part, utility conversions, and extensions thereof (collectively, "Future Patents"), in consideration for Assignee bearing all future costs and responsibilities related to the future filings, preparation, prosecution, maintenance, enforcement and defense of the Patent Applications and the Future Patent.

Now therefore, for and in consideration of one dollar (\$1.00) payable upon demand and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor does hereby sell, assign, and transfer to Assignee and its successors, assigns, and legal representatives, all right, title, and interest in and to the Patent Applications, and to all Future Patents, together with all claims, causes of action, and damages for past infringement, if any, of said Patent Applications and Future Patents; and Assignor hereby authorizes and requests the United States Patent and Trademark Office and other patent offices throughout the world to issue all Future Patents resulting therefrom (insofar as Assignor's interest is concerned) to Assignee.

Assignor also hereby sells, assigns, and transfers to Assignee and its successors, assigns, and legal representatives all right, title, and interest to the inventions disclosed in the Patent Applications and Future Patents throughout the world, including the right to file applications for and obtain patents, utility models, and industrial models, and designs for such inventions in Assignee's own name throughout the world including all rights of priority, all rights to publish cautionary notices reserving ownership of such inventions, and all rights to register such inventions in appropriate registries; and Assignor further agrees to execute any and all powers of attorney, applications, assignments, declarations, affidavits, and any other papers in connection therewith reasonably necessary to perfect such right, title, and interest in Assignee and its successors, assigns, and legal representatives.

In testimony whereof, Assignor has caused this Assignment to be executed by its officer(s) thereunto duly authorized, and Assignor hereby authorizes Assignee or its legal representative to insert in this instrument the filing date and serial number of any said application or any other information that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

Sankyo Co, Ltd., (Assignor)

Yakio Sugimura

executive Vice-President and Representative Director

Witness:

🗾 🗸 Kazuo Sato

Director of Intellectual

Property Department

PATENT REEL: 017075 FRAME: 0251

Date: 2-6 Sep 2-005

Schedule 1-Patent Applications

	Country	Application No.	Title	Filing Date	Publication Date	Publication No.
1	US	10/738,964	Isoquinolinone Derivatives and their Use as Therapeutic Agents	17-Dec-03	14-Oct-04	20040204447
2	TAIWAN	92136405	Isoquinolinone Derivatives and their Use as Therapeutic Agents	22-Dec-03		
3	PCT	US03/40275	Isoquinolinone Derivatives and their Use as Therapeutic Agents	17-Dec-03	15-Jul-04	WO2004/058717
4	EP	3814127.1	Isoquinolinone Derivatives and their Use as Therapeutic Agents	31-May-05		
5	AU	33012AA	Isoquinolinone Derivatives and their Use as Therapeutic Agents	17-Dec-03	22-Jul-04	

RECORDED: 10/11/2005

PATENT REEL: 017075 FRAME: 0252